Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
91 hedge funds and large institutions have $154M invested in Bellicum Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 32 reducing their positions, and 13 closing their positions.
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 88 → 91 (+3)
26% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $1.6M
27% less capital invested
Capital invested by funds: $212M → $154M (-$58.3M)
28% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.46M |
| 2 |
Millennium Management
New York
|
+$1.22M |
| 3 |
JP Morgan Chase
New York
|
+$745K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$580K |
| 5 |
VFA
Virtus Fund Advisers
Hartford,
Connecticut
|
+$400K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.72M |
| 2 |
Morgan Stanley
New York
|
-$1.15M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.07M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$998K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$779K |
BLCM Hedge Fund Activity: Q4 2017 in Review
91 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2017, worth a combined $154M — down 27% from $212M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BLCM positions and 13 closed out — a net gain of 3 holders — while 23 added to existing stakes and 32 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.72M sold.
- 91 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2017, up from 88 in Q3 2017.
- Funds reported $154M of Bellicum Pharmaceuticals, Inc. stock for Q4 2017, down 27% quarter-over-quarter.
- 16 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2017 and 13 closed out, a net change of +3 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2017 was Vanguard Group, an estimated $1.46M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2017 was Point72 Asset Management, an estimated $4.72M sold.
Based on aggregated 13F filings for Q4 2017.